Loading...
XNAS
VKTX
Market cap3.49bUSD
Jul 11, Last price  
31.11USD
1D
-0.58%
1Q
40.01%
Jan 2017
2,514.29%
IPO
253.52%
Name

Viking Therapeutics Inc

Chart & Performance

D1W1MN
XNAS:VKTX chart
No data to show
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
8.67%
Rev. gr., 5y
%
Revenues
0k
Net income
-110m
L+28.02%
0-146,247-21,884,183-23,403,988-14,731,822-20,577,665-22,063,000-25,779,000-36,051,000-54,002,000-67,379,000-85,895,000-109,963,000
CFO
-88m
L+19.64%
-200-78,235-1,591,423-8,731,494-11,071,263-14,757,767-18,755,000-24,752,000-21,777,000-47,586,000-48,397,000-73,376,000-87,790,000
Earnings
Jul 22, 2025

Profile

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
URL
https://vikingtherapeutics.com/
IPO date
Apr 29, 2015
Employees
22
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
150,921
101,119
70,646
Unusual Expense (Income)
NOPBT
(150,921)
(101,119)
(70,646)
NOPBT Margin
Operating Taxes
(1,488)
Tax Rate
NOPAT
(150,921)
(101,119)
(69,158)
Net income
(109,963)
28.02%
(85,895)
27.48%
(67,379)
24.77%
Dividends
Dividend yield
Proceeds from repurchase of equity
597,094
(7,121)
(5,969)
BB yield
-13.61%
0.41%
0.83%
Debt
Debt current
489
648
304
Long-term debt
1,749
2,196
2,824
Deferred revenue
Other long-term liabilities
Net debt
(900,374)
(359,235)
(152,357)
Cash flow
Cash from operating activities
(87,790)
(73,376)
(48,397)
CAPEX
Cash from investing activities
(553,366)
(179,086)
54,753
Cash from financing activities
612,464
271,376
4,163
FCF
(150,798)
(100,827)
(70,551)
Balance
Cash
902,612
362,079
155,485
Long term investments
Excess cash
902,612
362,079
155,485
Stockholders' equity
(488,694)
(378,332)
(293,150)
Invested Capital
1,370,091
728,335
440,036
ROIC
ROCE
EV
Common stock shares outstanding
109,037
94,347
76,834
Price
40.24
116.23%
18.61
97.98%
9.40
104.35%
Market cap
4,387,649
149.89%
1,755,798
143.10%
722,240
103.39%
EV
3,487,275
1,396,563
569,883
EBITDA
(168,094)
(100,827)
(70,355)
EV/EBITDA
Interest
88
1,488
Interest/NOPBT